Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00848237 · ClinicalTrials.gov registry record · NA

HALO Patient Registry: Ablation of Barrett's Esophagus

A NA study of Barrett Esophagus, sponsored by Medtronic - MITG.

Completed
Registry status
NA
Development phase
5,521
Enrollment target
1
Study location

NCT00848237 is a NA study of Barrett Esophagus that has completed, run by Medtronic - MITG. The registered enrollment target is 5,521 participants, above the 3,393-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (63% higher). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00848237, a NA study of Barrett Esophagus, has completed, sponsored by Medtronic - MITG.

COMPLETED
Registry status
NA
Development phase
5,521 participants
Enrollment target
1
Study location

Study Summary

The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD). The primary objective is to provide a tool for participating physician investigators to collect outcomes data related to the use of the HALO Ablation Systems.

Conditions Studied

Interventions

  • DEVICE Radiofrequency Ablation (HALO Ablation Systems)

Study Locations (1)

California

  • Gastrointestinal Associates and sites across the US - Knoxville and Other US Cities

Trial Details

FieldValue
Enrollment Target 5,521 participants
Start Date 2007-07
Est. Completion 2014-07
Phase NA

Sponsor

Medtronic - MITG

119 total trials

What the Registry Record Tells You About NCT00848237

The ClinicalTrials.gov registry entry for NCT00848237 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 5,521 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,393-participant average among 32 other Barrett Esophagus trials with a reported enrollment target (63% higher). The listed sponsor is Medtronic - MITG, which has 119 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Barrett Esophagus appearing as the primary indexed condition, and to 1 intervention - of which Radiofrequency Ablation (HALO Ablation Systems) is the first listed.

NCT00848237 reports 1 study location spanning 1 distinct geographic area - top geographies include California.

Frequently Asked Questions

What is clinical trial NCT00848237 about?

NCT00848237 is a clinical study titled "HALO Patient Registry: Ablation of Barrett's Esophagus". The HALO Patient Registry is a prospective/retrospective, multi-center patient registry. It provides a framework for treatment and follow-up of patients with Barrett's esophagus (non-dysplastic IM, LGD and HGD). The primary objective is to provide a tool for participating physician investigators to ...

What is the current status of trial NCT00848237?

This trial is currently completed. It is a NA study. The enrollment target is 5,521 participants. The study started on 2007-07. Estimated completion is 2014-07.

What conditions does trial NCT00848237 study?

This clinical trial studies the following conditions: Barrett Esophagus.

What interventions are being tested in trial NCT00848237?

The interventions under investigation include: Radiofrequency Ablation (HALO Ablation Systems) (DEVICE).

Who is sponsoring clinical trial NCT00848237?

This trial is sponsored by Medtronic - MITG, which has 119 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00848237 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Barrett Esophagus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.